Research: Biotechnology
Health Care » Biotechnology
As science continues to unravel new molecular pathways and disease targets, a vast array of new opportunities for drug discovery and development arise each day. Investors can capture the value creating inflection points at the research, Phase I, Phase II, Phase III, and post-market stage of biotechnology and pharmaceutical drug development. We help to identify the inflection points. We help investors navigate the science behind the clinical studies and interpret how the science impacts various stakeholders, from the Food and Drug Administration (FDA), to doctors, patients, hospitals, and insurance companies. As millions of new citizens engage in the new global economy, demand for therapeutics and the value of intellectual property is expected to grow in the U.S. and worldwide. Health care is a complex industry that already accounts for 16% of U.S. GDP. Given health care's growth trajectory, we believe investors cannot risk not participating in such an important industry. Given health care's growth trajectory in the U.S. and developing countries, we believe investors should participate in this important industry.
Click here to sign up for a Caris Research Account
Company Name
 |
Last Modified | Research |
|---|---|---|
| (SQNM) Sequenom Inc. No introduction text is currently available for this report. | 11/10/2009 | 2 |
| (VNDA) Vanda Pharmaceuticals No introduction text is currently available for this report. | 6/26/2008 | 1 |
Depending on the investment objectives and financial information specific to your situation, the investments discussed or recommended on this website may or may not be suitable for you. It is your responsibility to consider any investment decision carefully. The information contained on this website should not be construed as advice designed to meet the particular needs of any investor. Past performance is not necessarily indicative of future performance, and does not guarantee future results. The price and/or value of any security noted directly or indirectly on this website may fluctuate adversely to your interests, and/or those of other investors. Caris & Company accepts no liability whatsoever for loss or damage of any sort arising out of use of all or part of any information on this website.